2023-05-05T12:36:08-05:00 2022-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2022-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION D/B/A CURE ALZHEIMER'S FUND ALZH 7812373800 34 WASHINGTON ST 310 WELLESLEY HILLS MA 02481 TIMOTHY W ARMOUR PRESIDENT 7812373800 2023-05-05 1 TIMOTHY ARMOUR 999009999 0 SANDY ROSS P01399337 4012742001 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z CURE ALZHEIMER'S FUND TIMOTHY W ARMOUR 34 WASHINGTON ST 310 WELLESLEY HILLS MA 02481 47449763 0 X HTTP://CUREALZ.ORG/ X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. 7 6 33 35 0 0 26547838 32354655 0 0 32050 8359727 -7161 -6137 26572727 40708245 17719354 23431727 0 0 3128684 3951303 0 0 1662785 2317237 3229984 23165275 30613014 3407452 10095231 23967152 30192784 5766651 1734174 18200501 28458610 X TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 0 0 24460315 23431727 IN 2022, CURE ALZHEIMER'S FUND SUPPORTED 100 RESEARCH PROJECTS AT 59 LEADING RESEARCH INSTITUTIONS, FOR RESEARCH OUTPUT OF MORE THAN $24.4 MILLION. MANY PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF THE BRAIN'S INNATE IMMUNE SYSTEM AND THE CONTROL OF THE ENTRY AND EXIT OF MATERIALS FOR HEALTHY BRAIN FUNCTION. ADDITIONAL EXPENSES INCLUDE HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES. 3426801 CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 27887116 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 30 0 1 33 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 7 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X TIMOTHY W ARMOUR 7812383800 34 WASHINGTON STREET STE 310 WELLESLEY HILLS MA 02481 TIMOTHY ARMOUR PRESIDENT & CEO 40.00 X X 242641 0 8311 LAUREL LYLE SECRETARY & VP BOARD RELATIONS AND DEVELOPMENT 30.00 X X 105067 0 3711 HENRY MCCANCE CO-CHAIRMAN 5.00 X X 0 0 0 JEFFREY MORBY CO-CHAIRMAN 20.00 X X 0 0 0 PHYLLIS RAPPAPORT TREASURER 2.00 X X 0 0 0 ROBERT GREENHILL DIRECTOR 2.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 SHERRY SHARP TO 1222 DIRECTOR 2.00 X 0 0 0 KATHARINE HERMAN EVP DEVELOPMENT 40.00 X 327432 0 27571 BARBARA CHAMBERS EVP MARKETING & COMM. 40.00 X 194964 0 18645 MARGARET SMITH EVP, RESEARCH ADMIN 30.00 X 177400 0 21482 DOUGLAS HARPER SENIOR PHILANTHROPIC ADVISOR 40.00 X 185943 0 11501 LISA RAND VP MARKETING & COMM. 40.00 X 183812 0 16131 JOHN SLATTERY SVP MAJOR GIFTS 40.00 X 179157 0 6339 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 40.00 X 161817 0 21937 KELLY WESTERHOUSE VP GIVING 40.00 X 147868 0 10146 1906101 0 145774 13 0 1 0 PROPER VILLAINS INC 855 BOYLSTON STREET 10TH FLOOR BOSTON MA 02116 CREATIVE AND PRODUCTION SERVICES 297563 GRYPHON CONSULTING INC 21 DEAN ST BELMONT MA 02478 FINANCIAL & MGT CONSULTANT 175283 2 313024 32041631 5919199 32354655 93408 93408 14929740 6663421 8266319 8266319 8266319 71960 313024 78097 -6137 -6137 40708245 0 0 8353590 19201841 19201841 4229886 4229886 1127225 450674 88620 587931 2381842 1600832 366697 414313 65929 42857 11117 11955 130430 72783 18273 39374 245877 155536 28738 61603 15537 8491 3229 3817 149145 149145 75000 75000 30344 30344 545564 166869 190534 188161 777562 777562 245287 148991 37156 59140 89313 8057 81256 196349 111388 26933 58028 108919 36940 116 71863 250410 243623 6787 3907 3907 23125 3625 17605 1895 RESEARCH LAB EXPENSES 528064 528064 GIFT PROCESSING FEES 137649 70 137579 MISCELLANEOUS 53809 24097 9373 20339 30613014 27887116 1063113 1662785 4850918 2778505 4457855 7254987 1496905 1877735 160657 218532 54458 51416 6949 3042 12993868 17733326 0 326657 23967152 30192784 430625 129949 5103487 763585 232539 840640 5766651 1734174 X 16316372 26297281 1884129 2161329 18200501 28458610 23967152 30192784 10095231 162878 0 X 0 1 X 1 0 X 19798072 30497342 22873948 26576211 32354655 132100228 19798072 30497342 22873948 26576211 32354655 132100228 14939079 117161149 77320 83306 15472 4497 93408 274003 132374231 253982 0.88510 0.86760 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 75000 0 0 75000 0 PART II-B, LINE 1: A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. PART II-B, LINE 1(G) A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 7767 7767 0 46691 43649 3042 3042 ACCRUED PAYROLL AND RELATED 528365 LEASE PAYABLE 312275 840640 X 40840779 162878 -30344 132534 40708245 0 40708245 30582670 0 30582670 30344 30344 30613014 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVELS. THE ORGANIZATION ANNUALLY FILES IRS FORM 990 RETURNS OF ORGANIZATIONS EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. PART XI, LINE 2D - OTHER ADJUSTMENTS: INVESTMENT FEES -30,344. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH.LIST 59 _ 3SWHEELER - 03/04/21 10:18AM WORKSHEET SCHEDULE F _ 249550 _ 0 3494976 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH.LIST 64 _ 2SWHEELER - 03/08/22 10:46AM WORKSHEET SCHEDULE F _ 229425 658950 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 75960 0 0 0 0 0 0 4229886 0 4229886 EUROPE CIRCUITS: CHARACTERIZING EPIGENETIC BIOMARKERS OF HUMAN COGNITIVE AGING 252250 ACH 0 EUROPE PERSONALIZED DISEASE PREDICTION FOR ALZHEIMERS DISEASE USING PROTEOME PROFILING: THE EPIC4AD STUDY 54921 ACH 0 EUROPE CELLULAR VULNERABILITY TO AGEING 230000 ACH 0 EUROPE SFRP1 AS A THERAPEUTIC TARGET AND DIAGNOSTIC/PROGNOSTIC FACTOR INALZHEIMER'S DISEASE 172500 ACH 0 EUROPE NOVEL ENTRY ROUTES FOR THERAPEUTIC BIOLOGICALS TO THE BRAIN 172500 ACH 0 EUROPE EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMERS DISEASE NEUROINFLAMMATION 67500 ACH 0 EUROPE ADTC: IMPACT OF TAU MUTATIONS AND A ON TAU POST-TRANSLATIONAL MODIFICATIONS AND CONFORMATION 345000 ACH 0 EUROPE TURNING UP MITOPHAGY TO BLUNT ALZHEIMER TAU PATHOLOGIES 201250 ACH 0 NORTH AMERICA SEX MATTERS: UNDERSTANDING THE INFLUENCE OF SEX AND APOE GENOTYPE ON HIPPOCAMPAL PLASTICITY AND COGNITION 170200 ACH 0 NORTH AMERICA COMBINED HORMONE THERAPY AS A NOVEL TREATMENT FOR ALZHEIMERS DISEASE IN THE FACE OF A METABOLIC CHALLENGE: INFLUENCE OF SEX AND GENOTYPE 201250 ACH 0 EUROPE USING LONG-READ SEQUENCING TO INVESTIGATE THE MAPT LOCUS AND TRANSCRIPTS IN NEURODEGENERATION 201250 ACH 0 EUROPE CSF NEUROINFLAMMATORY SIGNATURE IN ALZHEIMERS DISEASE AND RELATED PROTEOPATHIES 139840 ACH 0 EUROPE STRUCTURAL MIMICRY IN MICROBIAL AND ANTIMICROBIAL AMYLOIDS CONNECTED TO NEURODEGENERATIVE DISEASES 124800 ACH 0 MIDDLE EAST AND NORTH AFRICA STRUCTURAL MIMICRY IN MICROBIAL AND ANTIMICROBIAL AMYLOIDS CONNECTED TO NEURODEGENERATIVE DISEASES 75960 ACH 0 EUROPE CSF NEUROINFLAMMATORY SIGNATURE IN ALZHEIMERS DISEASE AND RELATED PROTEOPATHIES 40710 ACH 0 EUROPE PERSONALIZED DISEASE PREDICTION FOR ALZHEIMERS DISEASE USING PROTEOME PROFILING: THE EPIC4AD STUDY 17816 ACH 0 EUROPE PERSONALIZED DISEASE PREDICTION FOR ALZHEIMERS DISEASE USING PROTEOME PROFILING: THE EPIC4AD STUDY 469160 ACH 0 EUROPE NEUROINFLAMMATION CONTRIBUTIONS TO ALZHEIMERS DISEASE: ROLE OF THE CHOROID PLEXUS 23000 ACH 0 EUROPE CHARACTERIZATION OF TAU PATHOLOGY HETEROGENEITY ACROSS THE ALZHEIMERS DISEASE SPECTRUM 201250 ACH 0 EUROPE EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMERS DISEASE NEUROINFLAMMATION 105000 ACH 0 EUROPE UNDERSTANDING, AND MIMICKING, THE BIOLOGICAL EFFECTS OF THE PLC2 P522R VARIANT THAT PROTECT AGAINST ALZHEIMERS DISEASE 173104 ACH 0 EUROPE TARGETING TAUOPATHIES WITH ANTISENSE OLIGONUCLEOTIDES TO SYNAPTOGYRIN-3 215625 ACH 0 NORTH AMERICA APOE CONSORTIUM: EFFECT OF CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY ON AMYLOID AND CEREBROVASCULAR PATHOLOGIES IN ANIMAL MODELS OF ALZHEIMERS DISEASE 287500 ACH 0 EUROPE DEEP MASS SPECTROMETRY PROFILING OF TAU AGGREGATES IN ALZHEIMERS DISEASE AND OTHER TAUOPATHIES 287500 ACH 0 0 0 0 0 0 0 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. PART III ACCOUNTING METHOD: FISHER ISLAND GOLF 384984 313024 71960 58806 19291 384984 313024 71960 58806 19291 78097 -6137 1 UNIVERSITY OF CONNECTICUT 263 FARMINGTON AVE FARMINGTON CT 06053 060772160 501 (C)(3) 230000 0 AD PATHOPHYSIOLOGY ALTERS THE LEVEL OF ELECTRICAL AND CHEMICAL SYNAPSE COUPLING IN THE NETWORK OF GABAERGIC PV+ INTERNEURONS EARLY IN DISEASE COURSE WASHINGTON UNIVERSITY 660 SOUTH EUCLID AVE MSC 8111-29-9000 ST LOUIS MO 63110 430653611 501 (C)(3) 252077 0 APOE: ASSESSING THE ADDED DIAGNOSTIC VALUE OF PERIPHERAL APOE PROTEIN LEVELS IN CURRENT BLOOD-BASED BIOMARKER ASSAYS FOR CNS AMYLOIDOSIS YALE 789 HOWARD AVE PO BOX 208051 NEW HAVEN CT 06520 060646973 501 (C)(3) 204238 0 BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMERS DISEASE CHARACTERIZED BY MRI MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 172500 0 EFFECTS OF DE-PALMITOYLATION AND ACAT INHIBITION ON AXONAL AB GENERATION VIA MAM-ASSOCIATED PALAPP DUKE 210 RESEARCH DRIVE DURHAM NC 27710 562247203 501 (C)(3) 194253 0 CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMERS PATHOLOGY IN MICE MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1639 NEW YORK NY 10029 136171197 501 (C)(3) 172500 0 ESTABLISHING THE MOLECULAR AND CELLULAR MECHANISMS AND BIOMARKERS OF APOE4-MEDIATED SUSCEPTIBILITY TO TAU-RELATED COGNITIVE IMPAIRMENTS UNIVERSITY OF VIRGINIA PO BOX 400328 CHARLOTTESVILLE VA 22904 546001796 501 (C)(3) 198932 0 TOXIC EFFECTS OF EXTRACELLULAR TAU OLIGOMERS ON NEURONS UNIVERSITY OF CALIFORNIA IRVINE 3014 GROSS HALL IRVINE CA 92697 952226406 501 (C)(3) 250000 0 NIC: EXAMINING THE ROLE OF HUMAN MICROGLIA IN THE TRANSITION BETWEEN PARENCHYMAL AND VASCULAR BETA-AMYLOID PATHOLOGY UNIVERSITY OF SOUTHERN CALIFORNIA 1501 SAN PABLO STREET LOS ANGELES CA 90033 951642394 501 (C)(3) 201250 0 PRENATAL INFLAMMATION EFFECTS ON BLOOD BRAIN BARRIER FUNCTION AND AD-RELATED PATHOLOGIES ACROSS THE LIFESPAN BRIGHAM AND WOMEN'S 60 FENWOOD ROAD BOSTON MA 02115 042312909 501 (C)(3) 287500 0 APOE CONSORTIUM: APOE4-MEDIATED DYSFUNCTION OF CD8 T CELL-MICROGLIA CROSSTALK IN ALZHEIMERS DISEASE MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 172500 0 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMERS DISEASE MAYO JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501 (C)(3) 172500 0 HARNESSING MENINGEAL LYMPHATICS AND IMMUNITY TO ALLEVIATE APOE4-INDUCED BRAIN DYSFUNCTION UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE BSB3092 LA JOLLA CA 92093 952872494 501 (C)(3) 287500 0 BEE: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMERS DISEASE HARVARD MEDICAL SCHOOL 200 LONGWOOD AVENUE WAB 336 BOSTON MA 02115 042103580 501 (C)(3) 250000 0 NIC: ASSESSING THE LINKS BETWEEN THE MS4A RISK GENES, MICROGLIA, AND ALZHEIMERS DISEASE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 752556007 501 (C)(3) 230000 0 RNA AND TAU SEED FORMATION UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 752556007 501 (C)(3) 287000 0 ADTC: THE ROLE OF VCP/P97 IN TAU PRION REPLICATION YALE 310 CEDAR ST BML330A NEW HAVEN CT 06519 060646973 501 (C)(3) 172500 0 ROLE OF MICROGLIAL MATRICELLULAR PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION DUKE 3550 HOSPITAL SOUTH DURHAM NC 27710 562247203 501 (C)(3) 199162 0 SEX DIFFERENCES IN ALZHEIMER'S DISEASE PROGRESSION: FRAMINGHAM HEART STUDY SALK 10010 NORTH TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 115000 0 CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMERS DISEASE PATHOLOGY ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE VAN ETTEN 3C5B BRONX NY 10461 830621846 501 (C)(3) 100000 0 APPLICATION OF MACHINE LEARNING METHODS IN ALZHEIMERS DISEASE CLINICAL TRIALS WEILL CORNELL 407 E 61ST STREET NEW YORK NY 10065 136094042 501 (C)(3) 172500 0 GUT MICROBIOTA, ENDOTHELIAL DYSFUNCTION AND TAU-MEDIATED COGNITIVE IMPAIRMENT UNIVERSITY OF SOUTHERN CALIFORNIA 3715 MCCLINTOCK AVE LOS ANGELES CA 90089 951642394 501 (C)(3) 219535 0 AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES WASHINGTON UNIVERSITY 425 SOUTH EUCLID AVE BOX 8111 ST LOUIS MO 63110 430653611 501 (C)(3) 172500 0 TARGETING REACTIVE ASTROCYTES FOR THERAPEUTIC INTERVENTION OF ALZHEIMERS DISEASE WEILL CORNELL 413 EAST 69TH STREET ROOM 920 NEW YORK NY 10021 136094042 501 (C)(3) 250000 0 DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMERS DISEASE MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1137 NEW YORK NY 10029 136171197 501 (C)(3) 217327 0 MICROGLIAL-SPECIFIC INPP5D KNOCKDOWN MODULATES BEHAVIOR, AMYLOIDOSIS, AND TAUOPATHY IN ALZHEIMER'S MOUSE MODELS UNIVERSITY OF VIRGINIA 409 LANE ROAD MR4- 6154 CHARLOTTESVILLE VA 22908 546001796 501 (C)(3) 201250 0 EXPLORING THE THERAPEUTIC POTENTIAL OF CLUSTERIN IN A PRECLINICAL MODEL OF ALZHEIMERS DISEASE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE DEPT 0651 LA JOLLA CA 92093 952872494 501 (C)(3) 250000 0 NIC: LEVERAGING ENHANCER LANDSCAPES TO DECODE AD RISK ALLELES IN MICROGLIA MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501 (C)(3) 172500 0 SYSTEMS INTEGRATION AND THERAPEUTICS TRANSLATION IN ALZHEIMERS DISEASE BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501 (C)(3) 171207 0 REVEALING NEW GENES AND PATHWAYS AT THE INTERSECTION OF LIPOTOXIC AND GENETIC RISK FOR ALZHEIMERS DISEASE MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 197500 0 AD4: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMERS DISEASE BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501 (C)(3) 248980 0 CIRCUITS: AUNIFIED APPROACH TO ACTIONABLE ALZHEIMERS DISEASE SIGNATURES WASHINGTON UNIVERSITY 660 SOUTH EUCLID AVE BOX 8111 ST LOUIS MO 63110 430653611 501 (C)(3) 345000 0 APOE CONSORTIUM: ROLE OF APOE ISOFORMS IN IMMUNE RESPONSES IN A MODEL OF TAUOPATHY MASSACHUSETTS GENERAL HOSPITAL 149 13TH STREET ROOM 2301 CHARLESTOWN MA 02129 041564655 501 (C)(3) 287500 0 NIC: BIOMARKER TOOL DEVELOPMENT IN CAF NEUROIMMUNE CONSORTIUM HARVARD MEDICAL SCHOOL 77 AVENUE LOUIS PASTEUR NRB 1054 BOSTON MA 02115 042103580 501 (C)(3) 201250 0 DISSECTING THE MODULATORY ROLES OF INTERLEUKIN-17 RECEPTOR D IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 286595 0 ADTC: HOW DO SOLUBLE TAU SPECIES REPLICATE? MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 250000 0 CREATION OF A FIBROBLAST/IPS CELL BANK TO FACILITATE PERIPHERAL/BRAIN COMPARISONS, AND ALLOW MOLECULAR INVESTIGATIONS INTO MOLECULAR MECHANISMS UNDERLYING DIFFERENCES IN DISEASE AGGRESSIVENESS MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 172500 0 REGIONAL VARIABILITY OF PATHOLOGY-ASSOCIATED PROPERTIES OF TAU IN POSTERIOR CORTICAL ATROPHY WHITEHEAD 455 MAIN STREET CAMBRIDGE MA 02142 061043412 501 (C)(3) 307500 0 CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMERS DISEASE PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 172500 0 DEVELOPMENT OF A MULTICELLULAR BRAIN MODEL TO STUDY BRAIN-VASCULAR-PERIPHERAL IMMUNE CELLS CROSSTALK INALZHEIMERS DISEASE MAYO JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501 (C)(3) 201250 0 ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMERS DISEASE MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 230590 0 AD4: HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMAN NEURAL CULTURE SYSTEMS WASHINGTON UNIVERSITY 660 SOUTH EUCLID AVENUE CAMPUS BOX 8118 ST LOUIS MO 06311 430653611 501 (C)(3) 172500 0 CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMERS DISEASE WASHINGTON UNIVERSITY 660 SOUTH EUCLID AVENUE MSC 8118-0041-01 ST LOUIS MO 06311 430653611 501 (C)(3) 345000 0 BEE: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMERS DISEASE BRIGHAM AND WOMEN'S 60 FENWOOD ROAD BOSTON MA 02115 042312909 501 (C)(3) 172500 0 ROLE OF CHECKPOINT MOLECULE TIM-3 IN MICROGLIA REGULATION IN ALZHEIMERS DISEASE BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501 (C)(3) 149500 0 NEUROINFLAMMATION CONTRIBUTIONS TO ALZHEIMERS DISEASE: ROLE OF THE CHOROID PLEXUS MSKCC 1275 YORK AVE NEW YORK NY 10065 131924236 501 (C)(3) 172500 0 THE ROLE OF IFITM3 AND GAMMA SECRETASE IN MICROGLIA NEW YORK UNIVERSITY 435 EAST 30TH STREET FL 11 NEW YORK NY 10016 135562308 501 (C)(3) 174883 0 THE ROLE OF ASTROCYTE-DERIVED TOXIC LIPIDS MEDIATING DEGENERATION IN ALZHEIMERS DISEASE NEW YORK UNIVERSITY 435 EAST 30TH STREET FL 11 NEW YORK NY 10016 135562308 501 (C)(3) 115000 0 NIC: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTIONS MASSACHUSETTS GENERAL HOSPITAL MGH EAST 149-2401 13TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 200417 0 CIRCADIAN PERTURBATIONS OF THE VASCULOME AND MICROGLIOME IN ALZHEIMERS DISEASE UNIVERSITY OF VIRGINIA 409 LANE ROAD MR4-6154 CHARLOTTESVILLE VA 22908 546001796 501 (C)(3) 172500 0 TARGETING A MASTER INNATE IMMUNE ADAPTOR MOLECULE IN ALZHEIMERS DISEASE WEILL CORNELL 1300 YORK AVENUE BOX 63 NEW YORK NY 10065 136094042 501 (C)(3) 172500 0 ROLE OF MICROGLIA IN DEGRADATION AND TRIMMING OF ALZHEIMERS AMYLOID BETA WASHINGTON UNIVERSITY 4488 FOREST PARK AVE SUITE 200 SAINT LOUIS MO 63108 430653611 501 (C)(3) 120015 0 CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0721 LA JOLLA CA 92093 952872494 501 (C)(3) 172500 0 FUNCTIONAL BASIS FOR NOVEL PKC K56R MUTATION IN ALZHEIMER'S DISEASE WAKE FOREST MEDICAL CENTER BOULEVARD WINSTONSALEM NC 27157 223849199 501 (C)(3) 172500 0 INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE INDUCTION AND MAINTENANCE UNIVERSITY OF MICHIGAN 2101 COMMONWEALTH BLVD SUITE A AND D ANN ARBOR MI 48105 386006309 501 (C)(3) 243407 0 NEUROBIOLOGICAL BASIS OF COGNITIVE IMPAIRMENT IN AFRICAN AMERICANS: DEEP PHENOTYPING OF OLDER AFRICAN AMERICANS AT RISK OF DEMENTIA MAYO JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501 (C)(3) 201250 0 EVALUATING TMEM106B ACCUMULATION IN AD CARNEGIE MELLON 5000 FORBES AVE GHC 7711 PITTSBURGH PA 15213 250969449 501 (C)(3) 200000 0 CIRCUITS: INTERPRETING ALZHEIMERS DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS BRIGHAM AND WOMEN'S 181 LONGWOOD AVE BOSTON MA 02115 042312909 501 (C)(3) 183562 0 IMMUNOTHERAPIES TARGETING THE MICROBIOTA TO PREVENT COGNITIVE DECLINE IN ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S 60 FENWOOD ROAD SUITE 10002J BOSTON MA 02115 042312909 501 (C)(3) 201250 0 NEUROIMMUNE CONNECTOME PERTURBATIONS IN ALZHEIMERS DISEASE BARROW 240 W THOMAS RD SUITE 403 PHOENIX AZ 08501 999999999 501 (C)(3) 170877 0 HARNESSING BIG DATA TO UNDERSTAND ALZHEIMER'S DISEASE RISK BOSTON UNIVERSITY 72 E CONCORD STREET ROUSSARIE LAB L817 BOSTON MA 02118 042103547 501 (C)(3) 167707 0 APOE CONSORTIUM: MODULATION OF SELECTIVE NEURONAL VULNERABILITY IN ALZHEIMERS DISEASE BY APOE MOUNT SINAI 1425 MADISON AVE NEW YORK NY 10029 136171197 501 (C)(3) 172500 0 STRESS AND NEUROVASCULAR-IMMUNE NETWORKS IN ALZHEIMERS DISEASE NORTHWESTERN 303 E SUPERIOR AVE TARRY 7-770 CHICAGO IL 60611 362167817 501 (C)(3) 286357 0 ADTC: THE ROLE OF A-INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY WEILL CORNELL 1300 YORK AVENUE NEW YORK NY 10065 136094042 501 (C)(3) 287500 0 BEE: BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CSF AND LYMPH FOLLOWING CHANGES IN BRAIN FLUID DYNAMICS JOHNS HOPKINS 725 N WOLFE ST BALTIMORE MD 21205 999999999 501 (C)(3) 201250 0 HUMAN BRAIN CD33 LIGAND, RPTPS3L, LIMITS MICROGLIAL PHAGOCYTOSIS AND CONTRIBUTES TO ALZHEIMERS DISEASE PROGRESSION WEILL CORNELL 413 EAST 69TH STREET NEW YORK NY 10065 136094042 501 (C)(3) 172500 0 IDENTIFICATION OF CD33 ANTAGONISTS UNIVERSITY OF CHICAGO 947 EAST 58TH STREET MC0928 CHICAGO IL 60637 362177139 501 (C)(3) 210871 0 IDENTIFYING THE SEX-SPECIFIC ROLES OF THE GUT-MICROBIOME-BRAIN AXIS IN A MOUSE MODEL OF AB AMYLOIDOSIS UNIVERSITY OF CHICAGO 947 EAST 58TH STREET MC0926 CHICAGO IL 60637 362177139 501 (C)(3) 229033 0 TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT ROCKEFELLER 1230 YORK AVE BOX 252 NEW YORK NY 10065 131624158 501 (C)(3) 172500 0 STIMULATING SYNAPTIC PROTEASOME ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE BOSTON CHILDREN'S HOSPITAL BLACKFAN CIRCLE CLS 12257 BOSTON MA 02115 042774441 501 (C)(3) 300000 0 NIC: UNDERSTANDING THE CONSEQUENCES OF NON-CODING AD RISK ALLELES ON MICROGLIA FUNCTION STONY BROOK DEPARTMENT OF COMPUTER SCIENCE ROOM 137 STONY BROOK NY 11794 161514621 501 (C)(3) 82166 0 BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMERS DISEASE CHARACTERIZED BY MRI MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 1955000 0 THECUREALZALZHEIMERS GENOME PROJECT TUFTS 136 HARRISON AVENUE ST 328A BOSTON MA 02111 042103634 501 (C)(3) 172500 0 IN VIVO CHARACTERIZATION OF A LOSS OF FUNCTION GGA3 RARE VARIANT ASSOCIATED WITH AD NORTHWESTERN 300 E SUPERIOR ST TARRY 8-711 CHICAGO IL 60611 362167817 501 (C)(3) 246804 0 SINGLE NUCLEUS RNA SEQUENCING ANALYSIS OF ACE1 R1284Q KNOCKIN MICE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 513 PARNASSUS AVE MSB 1349C SAN FRANCISCO CA 94117 946036493 501 (C)(3) 201250 0 ROLE OF THE CIRCULATING EXERKINE GPLD1 IN AMELIORATING ALZHEIMERS DISEASE PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 114 16TH STREET CHARLESTOWN MA 02129 041564655 501 (C)(3) 177675 0 G2T, AD4 AND GENERAL SCIENTIFIC SUPPORT BRIGHAM AND WOMEN'S 60 FENWOOD ROAD BOSTON MA 02115 042312909 501 (C)(3) 201250 0 TARGETING THE MICROBIOME AND INNATE IMMUNITY IN ALZHEIMERS DISEASE HOUSTON METHODIST 6670 BERTNER AVENUE R6 SOUTH HOUSTON TX 77030 760094743 501 (C)(3) 225000 0 AD4: UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATICS ALZHEIMERS DRUG REPOSITIONING MASSACHUSETTS GENERAL HOSPITAL 149 13TH ST CHARLESTOWN MA 02129 041564655 501 (C)(3) 172500 0 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMERS DISEASE STANFORD 290 JANE STANFORD WAY E367 CHEM-H/NEURO BUILDING STANFORD CA 94305 941156365 501 (C)(3) 172500 0 A TRANSCRIPTIONAL REJUVENATION SIGNATURE FOR ALZHEIMERS DISEASE BOSTON UNIVERSITY 72 EAST CONCORD ST L-603 BOSTON MA 02118 042103547 501 (C)(3) 197500 0 AD4: BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS UNIVERSITY OF CALIFORNIA SAN FRANCISCO 513 PARNASSUS AVENUE HSW 1346 SAN FRANCISCO CA 94143 946036493 501 (C)(3) 201250 0 UNDERSTANDING HOW HUMAN BRAIN VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY 660 S EUCLID AVENUE CAMPUS BOX 8103 ST LOUIS MO 63110 430653611 501 (C)(3) 172500 0 NEURONAL SUBTYPE-SPECIFIC MODELING OF ALZHEIMERS DISEASE BY DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS UNC-CHAPEL HILL 4108 MARSICO HALL CAMPUS BOX 7363 CHAPEL HILL NC 27599 566001393 501 (C)(3) 172500 0 SMALL MOLECULE ACTIVATORS OF PLC-Y2 AS NOVEL THERAPEUTICS FOR ALZHEIMERS DISEASE BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA BCM230 HOUSTON TX 77030 741613878 501 (C)(3) 167637 0 ELUCIDATING THE ROLE OF SOLUBLE EPOXIDE HYDROLASE AND ARACHIDONIC ACID METABOLISM IN NEUROINFLAMMATION AND ALZHEIMERS DISEASE 86 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. X X X X 0 0 0 0 0 0 0 0 0 KATHARINE HERMAN EVP DEVELOPMENT 327432 0 0 0 0 0 10128 0 17443 0 355003 0 0 0 TIMOTHY ARMOUR PRESIDENT & CEO 242641 0 0 0 0 0 7351 0 960 0 250952 0 0 0 BARBARA CHAMBERS EVP MARKETING & COMM. 194964 0 0 0 0 0 6188 0 12457 0 213609 0 0 0 LISA RAND VP MARKETING & COMM. 183812 0 0 0 0 0 5777 0 10354 0 199943 0 0 0 MARGARET SMITH EVP, RESEARCH ADMIN 177400 0 0 0 0 0 5802 0 15680 0 198882 0 0 0 DOUGLAS HARPER SENIOR PHILANTHROPIC ADVISOR 185943 0 0 0 0 0 5585 0 5916 0 197444 0 0 0 JOHN SLATTERY SVP MAJOR GIFTS 179157 0 0 0 0 0 5457 0 882 0 185496 0 0 0 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 161817 0 0 0 0 0 5188 0 16749 0 183754 0 0 0 KELLY WESTERHOUSE VP GIVING 147868 0 0 0 0 0 4609 0 5537 0 158014 0 0 0 PROPER VILLIANS INC A PRINCIPAL OF THE VENDOR IS THE SPOUSE OF A KEY EMPLOYEE 279563 CREATIVE AND PRODUCTION SERVICES 0 X 56 5919199 SALE PRICE 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH FIRST REPUBLIC BANK AND BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY AND JACQUELINE MORBY ARE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE PRESIDENT AND CONTRACT CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE PRESIDENT AND ALL OTHER EMPLOYERS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.